Join the Seborrheic Dermatitis group to help and get support from people like you.
Seborrheic Dermatitis News
FDA Approves Arcutis’ Zoryve (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
Zoryve foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration...
Ask a question
To post your own question to this support group, sign in or create an account.